Entries by Maren Kühr

,

Can Europe finance and keep its biotech winners?

The recent resurgence of life sciences IPOs in the US highlights a persistent ­structural imbalance: Europe generates world-class science but struggles to finance and retain it. The ­European Life Sciences Coalition was created to address this gap by mobilizing institutional ­capital and strengthening the policy framework needed to scale European innovation at home.

,

Where Life Science Scales in Basel

The Basel region is one of the world’s leading life-science clusters. ­Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the industry continues to grow, the demand for ­scalable laboratory and office environments within this innovation ecosystem is increasing.

,

Europe’s pivotal choice: Vaccination is health security

The COVID 19 pandemic demonstrated that Europe can move fast, take risk, and deliver world class vaccines when political will, science and capital are aligned. Treating vaccines as strategic assets, backed by sustained political and financial support, will be key to maintaining Europe’s long-term investment in public health and innovation.

Mitigating regulatory risk with holistic CMC strategies

As advanced therapeutic medicinal products (ATMPs) and other next-generation biologics move toward approval, Chemistry, Manufacturing and Controls (CMC) continues to be the most frequent source of regulatory concern. This article highlights recurring CMC barriers and best practices to mitigate approval delays or refusals.

Leadership change

Swiss biotech company Anaveon has appointed a new Chief Executive Officer. As the company announced in March, experienced biopharma executive Thaminda Ramanayake will take over the leadership of the Basel-based firm.

Is the Unified Patent Court affordable for small biotechs?

The Unified Patent Court and the unitary patent were established to make patent litigation in Europe easier, faster and more affordable. It has been particularly emphasized that the new system was designed to enable small and medium-sized enterprises to enforce their rights more effectively and rapidly. The reality now suggests differently. Litigation in Europe has become quite fragmented, more complex and more expensive than ever – a nice playground for deep pockets.

New CFO with Novartis experience

In March, Mukul Mehta took over as the new Chief Financial Officer at Basel-based Biotech and Pharma Company Novartis. At the same time, he became a member of the Executive Committee.